Patients with systemic lupus erythematosus and sustained low hydroxychloroquine blood levels may be at significantly ...
If envudeucitinib were to secure approval in SLE, it could become one of the first oral targeted therapies to reach the ...
LUMUS trial did not meet its primary and secondary endpoints in the overall trial population –– Robust responses in the prespecified subgroup ...
Adding obinutuzumab to standard therapy may improve disease control and reduce flares in adults with active systemic lupus erythematosus.
Alumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population.
Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage ...
Neuropsychiatric symptoms are common in systemic lupus erythematosus (SLE), typically featuring impaired cognition and ...
InvestorsHub on MSN
Alumis phase 2b lupus trial misses primary and secondary endpoints
Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe ...
Novartis and Bristol Myers Squibb have paused their CAR-T trials for lupus and other autoimmune diseases to review safety ...
Objective This study aimed to compare 25-hydroxyvitamin D (25-(OH)D) levels and peripheral lymphocyte subsets between ...
Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results